Biomarker Platform: BA325

Novel oncology gene panel that provides global insight into cancer response to treatments to accelerate drug discovery and development

BIOARRAY identified RNA-biomarkers representing healthy organization phenotypes. This approach based on phenotypes identified genes important to healthy (non-malignant) cell organization in a physiologically relevant context. As a result the selected biomarkers have greater utility in testing tumor samples because:

  • Of the 325 genes identified, 251 are novel and not present in nine other commercially available oncology gene panels
  • BA325 contains 32 genes that are currently drug treatment targets and provides comprehensive information about oncology drug sensitivity and resistance
  • While other oncology gene panels are proliferation centric, BIOARRAY’s genes cover diverse interconnected cell signaling pathways

BA325 technically validated assay is currently available in conjunction with the company’s bioinformatics pipeline for research and development projects.

Patient Stratification:

With the advent of new developments of drug combinations and targeted treatments, the ability to stratify patient populations for clinical trial accuracy has become increasingly important. Specifically, BIOARRAY’s BA325 can be used as a framework to stratify categories of patients, select patients for clinical trials, and develop companion diagnostics by providing a more in-depth and comprehensive view of gene expression profiles and key cellular signaling pathways.

Sample Specifications:

  1. Species: Human
  2. Expected Number of Samples: Project specific – high throughput
  3. Format of Samples to be Received: Tissue (FFPE, Blood, or Frozen), Cell extract (Frozen), or RNA
  4. Storage Conditions: RNA samples should be shipped on dry ice and stored at -70C.
  5. Sample tracking: Barcode.

Assay Specifications:

  1. Assay: Custom designed Nanostring’s n-counter assay for 325 RNA-biomarkers
  2. Data Collection: Data will be produced by the n-Counter according to validated standard operating procedures
  3. Data Analysis: Data will be analyzed by the company’s bioinformatics pipeline

Data Analysis:

The company’s bioinformatics pipeline is technology platform agnostic. We can analyze gene expression and genomic data from Affymetrix, Agilent, Illumina, and Nanostring platforms.

The ability to analyze large amounts of complex data and generate novel information sets Bioarray apart from others.  New information on pathways and their interconnections, the development of evidence-based biomarkers, and resulting actionable information set the foundation for optimization of drug discovery, and development of predictive tests and companion diagnostics.!/4292/presentation/1589!/4292/presentation/6659



BIOARRAY’s Lead Predictive Test BA100

The Company’s lead test, BA100, predicts the likelihood that a breast cancer patient will achieve pathological complete response (pCR) as a result of standard-of-care anthracyline/taxane neoadjuvant chemotherapy. Easy to interpret test results provided to the physician encompass quantitative probability scores and accurate personalized information that can help doctors and patients planning the optimal course of treatment.

The candidates for this test are newly diagnosed invasive breast cancer patients with locally advanced, or early stage high risk disease independent of lymph node status or subtype, that are eligible for neoadjuvant chemotherapy.

The test is applicable to triple negative breast cancers and can accelerate the development of new targeted therapies for this breast cancer subtype by stratifying patients upfront before they receive any treatments.

BIOARRAY’s ongoing research and technology development efforts are aimed at expanding the impact of molecular information to guide the treatment of other types of cancer in addition to our current test for invasive breast cancer. The cancer treatment paradigm is evolving rapidly, and BIOARRAY is an integral part of that evolution.